JACQUELINE GILLERN: Open Payments
NPI 1063982759 · WAYMART, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,414 in 72 payments from 11 companies in 2025. Trend: 2023 $575 · 2024 $1,327 · 2025 $1,414
Food & beverage: $1,414
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $266 |
| Otsuka America Pharmaceutical, Inc. | 7 | $193 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $179 |
| Neurocrine BioSciences, Inc. | 12 | $162 |
| E.R. Squibb & Sons, L.L.C. | 4 | $154 |
| Vanda Pharmaceuticals Inc. | 6 | $144 |
| Janssen Pharmaceuticals, Inc | 6 | $136 |
| ABBVIE INC. | 5 | $101 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
Products named: UZEDY, REXULTI, CAPLYTA, INGREZZA, COBENFY, FANAPT, INVEGA SUSTENNA, VRAYLAR.
Industry payments across PA — which companies pay providers there.
